Literature DB >> 33185790

IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.

Hao Li1, George C Tsokos2.   

Abstract

In inflammatory rheumatic disorders, the immune system attacks and damages the connective tissues and invariably internal organs. During the past decade, remarkable advances having been made towards our understanding on the cellular and molecular mechanisms involved in rheumatic diseases. The discovery of IL-23/IL-17 axis and the delineation of its important role in the inflammation led to the introduction of many needed new therapeutic tools. We will present an overview of the rationale for targeting therapeutically the IL-23/IL-17 axis in rheumatic diseases and the clinical benefit which has been realized so far. Finally, we will discuss the complex interrelationship between IL-23 and IL-17 and the possible uncoupling in certain disease settings.

Entities:  

Keywords:  Biologics; IL-23/IL-17 axis; Inflammatory rheumatic disorders

Year:  2020        PMID: 33185790     DOI: 10.1007/s12016-020-08823-4

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  177 in total

Review 1.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

Review 2.  Psoriasis.

Authors:  Frank O Nestle; Daniel H Kaplan; Jonathan Barker
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

Review 3.  Autoimmunity and organ damage in systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  Nat Immunol       Date:  2020-05-04       Impact factor: 25.606

Review 4.  Targeting IL-17 and TH17 cells in chronic inflammation.

Authors:  Pierre Miossec; Jay K Kolls
Journal:  Nat Rev Drug Discov       Date:  2012-10       Impact factor: 84.694

Review 5.  Rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Iain B McInnes
Journal:  Lancet       Date:  2016-05-03       Impact factor: 79.321

Review 6.  Axial spondyloarthritis.

Authors:  Joachim Sieper; Denis Poddubnyy
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

Review 7.  Autoimmunity, end organ damage, and the origin of autoantibodies and autoreactive T cells in systemic lupus erythematosus.

Authors:  Janet E Lewis; Shu Man Fu; Felicia Gaskin
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

8.  Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines.

Authors:  M Chabaud; F Fossiez; J L Taupin; P Miossec
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

9.  Human IL-17: a novel cytokine derived from T cells.

Authors:  Z Yao; S L Painter; W C Fanslow; D Ulrich; B M Macduff; M K Spriggs; R J Armitage
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422

10.  A proposed classification of the immunological diseases.

Authors:  Dennis McGonagle; Michael F McDermott
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

View more
  2 in total

1.  Immune-inflammatory and hypothalamic-pituitary-adrenal axis biomarkers are altered in patients with non-specific low back pain: A systematic review.

Authors:  Juan P Sanabria-Mazo; Ariadna Colomer-Carbonell; Meritxell Carmona-Cervelló; Albert Feliu-Soler; Xavier Borràs; Mar Grasa; Montserrat Esteve; Michael Maes; Sílvia Edo; Antoni Sanz; Juan V Luciano
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

2.  Measurement of pre-treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients.

Authors:  Fei Peng; Fengyun Chen; Huijun Wen; Jie Bai; Yuping Tian
Journal:  Int J Rheum Dis       Date:  2022-06-12       Impact factor: 2.558

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.